Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non‐Small Cell Lung Cancer Harboring Only EGFR Mutations

The recommended daily dose of erlotinib was determined for patients with all types of non‐small cell lung cancer (NSCLC). We determined the optimal dose (OD) in patients with NSCLC harboring only epidermal growth factor receptor (EGFR) sensitizing mutations. EGFR‐tyrosine kinase inhibitor‐naïve pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Yuichiro, Ishizuka, Naoki, Sano, Kazumi, Hirano, Satoshi, Suzuki, Manabu, Naka, Go, Sugiyama, Haruhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719385/
https://www.ncbi.nlm.nih.gov/pubmed/32315488
http://dx.doi.org/10.1111/cts.12796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719385/
https://www.ncbi.nlm.nih.gov/pubmed/32315488
http://dx.doi.org/10.1111/cts.12796

Ejemplares similares